Genome and Company Revenue and Competitors

Genome & Company is a clinical stage biotechnology company based in Republic of Korea that focuses on discovering and developing the next waves of innovative therapeutics in immuno-oncology through diverse modalities of microbiome, novel target immune checkpoint inhibitors and fusion proteins to fulfill the unmet needs of cancer patients. We are the first Asian company to sponsor clinical trial of combination therapy of anti-cancer microbiome and anti-PD1/anti-PD-L1 drug on combinational therapy of Merck KGaA, Darmstadt, Germany/Pfizer's avelumab (BAVENCIO®) with Genome & Company's GEN-001 microbiome therapeutic Recently we have become the majority shareholder of Scioto Biosciences, and both companies have agreed to multilaterally cooperate on the research of new drug candidates. Genome & Company continues its efforts to transfer listing from KONEX to KOSDAQ within this year. On July 15, Genome & Company has passed the technology evaluation process for the Technology Growth Company.